Prompt clinical response to secukinumab in patients with axial spondyloarthritis: real-life observational data from three Italian referral centers

Aims: Primary aim of our study was to evaluate short-term efficacy of secukinumab (SCK) in axial spondyloarthritis (axSpA); secondary aims were to identify differences in the clinical and laboratory assessment, according to dosage administered and biologic treatment-lines, and to report any adverse event. Methods: Patients with axSpA consecutively treated with SCK were enrolled. Laboratory assessment was based on erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) evaluation; clinical assessment was performed with the Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Data were recorded at baseline and at the 3-month visit. Results: Twenty-one patients (7 males; 14 females) were enrolled; both BASDAI and ASDAS-CRP showed a statistically significant reduction between the baseline and the 3-months visit (p